Gilead Sciences, Inc. $GILD Stock: Chicago Partners Investment Group LLC Grows Holdings

08 Nov 2026, 08:49 by Mitch Edgeman · The Markets Daily

Chicago Partners Investment Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 41.8% in the third quarter, HoldingsChannel.com reports. The firm owned 14,288 shares of the biopharmaceutical company’s stock after purchasing an additional 4,209 shares during the period. Chicago Partners Investment Group LLC’s holdings in Gilead Sciences were worth $2,229,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of Nova Scotia bought a new position in shares of Gilead Sciences in the second quarter worth approximately $100,056,000. OMERS ADMINISTRATION Corp purchased a new stake in Gilead Sciences in the second quarter valued at approximately $55,754,000. Groupe la Francaise lifted its position in Gilead Sciences by 30.9% during the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. lifted its position in Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $6,251,000. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 239,310 shares of company stock valued at $38,945,617 over the last three months. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Stock Down 0.4%

Shares of GILD opened at $166.89 on Friday. The firm has a market cap of $207.00 billion, a P/E ratio of -52.81 and a beta of 0.35. The stock has a 50 day simple moving average of $153.04 and a two-hundred day simple moving average of $140.94. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.47 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a report on Friday, October 30th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Citigroup upped their target price on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Scotiabank increased their target price on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Finally, Wells Fargo & Company raised their price target on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.15.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).